Drug Type Small molecule drug |
Synonyms 2879552, GSK 2879552, GSK-2877592 |
Target |
Mechanism KDM1A inhibitors(Lysine-specific histone demethylase 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC23H28N2O2 |
InChIKeyLRULVYSBRWUVGR-MMYMAHBISA-N |
CAS Registry1401966-63-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myelodysplastic Syndromes | Phase 2 | US | 31 Jul 2017 | |
Myelodysplastic Syndromes | Phase 2 | ES | 31 Jul 2017 | |
Refractory acute myeloid leukemia | Phase 1 | US | 27 Aug 2014 | |
Refractory acute myeloid leukemia | Phase 1 | AU | 27 Aug 2014 | |
Refractory acute myeloid leukemia | Phase 1 | CA | 27 Aug 2014 | |
Relapsing acute myeloid leukemia | Phase 1 | US | 27 Aug 2014 | |
Relapsing acute myeloid leukemia | Phase 1 | AU | 27 Aug 2014 | |
Relapsing acute myeloid leukemia | Phase 1 | CA | 27 Aug 2014 | |
Small Cell Carcinoma | Phase 1 | US | 04 Feb 2014 | |
Small Cell Carcinoma | Phase 1 | FR | 04 Feb 2014 |
NCT02034123 (Pubmed) Manual | Phase 1 | 29 | nyufqqxzfm(kwrbvpnrda) = Twelve serious AEs (SAEs) were reported by nine patients, the most common of which was encephalopathy (four SAEs) pnpxgswnvd (kdssiebgjb ) | Negative | 01 Oct 2019 | ||
Phase 1 | 41 | (Part 1:GSK2879552 1mg QD) | hetnrjtsmh(sbyfdcvhbq) = clgdbvqkvl rxleomwesy (gcxyievcty, hspnrnoxel - luaxuijomy) View more | - | 28 Jun 2019 | ||
(Part 1: GSK2879552 2mg QD) | hetnrjtsmh(sbyfdcvhbq) = unkkgbtubq rxleomwesy (gcxyievcty, ykwwnzhjxw - jsvkmfhmqo) View more |